Gain Therapeutics, Inc. filed a Form 8-K on October 28, 2026, disclosing the appointment of Jeanette Weidner as Vice President, Finance, principal financial officer, and principal accounting officer, effective October 28, 2026.

Key Highlights

  • Appointment effective October 28, 2026: Jeanette Weidner was appointed Vice President, Finance, and will serve as the company's principal financial officer and principal accounting officer.
  • Annual base salary of $275,000: The employment agreement sets Ms. Weidner's base salary at $275,000, with an annual incentive cash bonus target initially set at 35% of base salary.
  • Stock option grant of up to 130,000 shares: Ms. Weidner will receive an option to purchase up to 130,000 shares of common stock under the company's 2022 Equity Incentive Plan, vesting over four years.
  • 18 years of accounting and finance experience: According to the filing, Ms. Weidner has more than a decade of experience specifically in the life sciences industry.
  • Prior role at Senseonics Holdings Inc.: Ms. Weidner most recently served as a financial consultant for Senseonics Holdings Inc. (Nasdaq: SENS) from March 2025 to October 2026.
  • Change of Control severance provision: If terminated in connection with a Change of Control, Ms. Weidner would be eligible for 12 months of base salary severance and 100% accelerated vesting of unvested stock awards.

Weidner Appointment Details and Compensation Terms at Gain Therapeutics

According to the Form 8-K filed with the SEC, Gain Therapeutics, Inc. (NASDAQ:GANX) appointed Jeanette Weidner, age 44, as Vice President, Finance, on October 22, 2026, with an effective date of October 28, 2026. In this role, the filing states, Ms. Weidner will also serve as the company's principal financial officer and principal accounting officer. The filing notes that there are no arrangements or understandings between Ms. Weidner and any other persons pursuant to which she was appointed, and no family relationships between Ms. Weidner and any directors or executive officers of the company.

The company disclosed that it entered into an employment agreement with Ms. Weidner effective October 28, 2026, providing an annual base salary of $275,000. Ms. Weidner is also eligible for an annual incentive cash bonus with a target initially set at 35% of her annual base salary, as determined by the Board in its sole discretion. The filing further discloses that the company will grant Ms. Weidner an option to purchase up to 130,000 shares of common stock at an exercise price equal to the fair market value on the date of grant, with 25% vesting on the first anniversary of the effective date and the balance vesting in equal monthly installments over the remaining three years, subject to continuous employment.

The filing describes severance provisions under the employment agreement. In the event of termination without "Cause," for "Good Reason," or upon death or "Disability" on or after three months following the effective date, Ms. Weidner would be eligible for six months of base salary severance and up to six months of COBRA continuation coverage. If such termination occurs on the date of, or within twelve months following, a "Change of Control," the filing states the severance increases to twelve months of base salary, twelve months of COBRA coverage, a pro-rated annual bonus, an additional target bonus, and 100% accelerated vesting of unvested stock awards, in each case subject to Ms. Weidner executing a separation agreement with a general release of claims.

What Was Disclosed

Gain Therapeutics disclosed the appointment of Jeanette Weidner as Vice President, Finance, principal financial officer, and principal accounting officer, along with the key terms of her employment agreement, including salary, bonus eligibility, a stock option grant, and severance provisions.